AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
1.230
-0.060 (-4.65%)
Apr 25, 2025, 9:35 AM EDT - Market open
AN2 Therapeutics Analyst Ratings
Total Analysts
4
Consensus Rating
Buy
Price Target
$3.50
Upside
+184.55%
Ratings History
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $5 | Buy | Reiterates | $5 | +306.50% | Mar 26, 2025 |
Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $5 | Buy | Reiterates | $5 | +306.50% | Feb 25, 2025 |
JMP Securities | JMP Securities | Buy Reiterates $5 | Buy | Reiterates | $5 | +306.50% | Feb 3, 2025 |
JMP Securities | JMP Securities | Buy Reiterates $5 | Buy | Reiterates | $5 | +306.50% | Nov 19, 2024 |
TD Cowen | TD Cowen | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 18, 2024 |
JMP Securities | JMP Securities | Buy Maintains $6 → $3 | Buy | Maintains | $6 → $3 | +143.90% | Aug 9, 2024 |
Leerink Partners | Leerink Partners | Hold → Buy Upgrades n/a | Hold → Buy | Upgrades | n/a | n/a | Jul 3, 2024 |
Evercore ISI Group | Evercore ISI Group | Hold Maintains $7 → $2 | Hold | Maintains | $7 → $2 | +62.60% | May 16, 2024 |
JMP Securities | JMP Securities | Hold → Buy Upgrades $6 | Hold → Buy | Upgrades | $6 | +387.80% | Apr 2, 2024 |
Oppenheimer | Oppenheimer | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Apr 1, 2024 |
Leerink Partners | Leerink Partners | Buy → Hold Downgrades $23 → $7 | Buy → Hold | Downgrades | $23 → $7 | +469.11% | Feb 13, 2024 |
Evercore ISI Group | Evercore ISI Group | Buy → Hold Downgrades $25 → $7 | Buy → Hold | Downgrades | $25 → $7 | +469.11% | Feb 12, 2024 |
Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Feb 12, 2024 |
JMP Securities | JMP Securities | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Feb 12, 2024 |
JMP Securities | JMP Securities | Buy Initiates $30 | Buy | Initiates | $30 | +2,339.02% | Jan 4, 2024 |
Oppenheimer | Oppenheimer | Buy Maintains $20 → $24 | Buy | Maintains | $20 → $24 | +1,851.22% | Mar 30, 2023 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.